©2024 Stanford Medicine
Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy
Not Recruiting
Trial ID: NCT01644097
Purpose
This randomized phase II clinical trial studies probiotic supplementation in preventing
treatment-related diarrhea in patients with cancer undergoing chemotherapy. Probiotics may
help prevent diarrhea caused by treatment with chemotherapy.
Official Title
A Phase II Feasibility and Correlative Study of Probiotic Supplementation in Cancer Patients Receiving Chemotherapy or Tyrosine Kinase Inhibitors (TKIs)
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Any patient with a documented malignancy initiating treatment including (as a single
agent or in combination with other drugs) any one of the following cancer
therapeutics:
o Fluorouracil (5FU), capecitabine, irinotecan, paclitaxel, docetaxel, cabazitaxel,
crizotinib, sorafenib, sunitinib, erlotinib, or lapatinib
- Any pathologically confirmed malignancy for which the patient would receive any of the
listed cancer therapeutics
- Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2
- Patient must have an estimated life expectancy of at least 6 months
- Absolute neutrophil count (ANC) > 1500
- Platelets > 100K
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x ULN (upper
limit normal)
- Serum bilirubin < 1.5 x ULN
- Serum creatinine < 1.5 x ULN
- Ability to understand and the willingness to sign a written informed consent document
and comply with the treatment protocol
Exclusion Criteria:
- Patients currently undergoing treatment with the above listed therapeutics at time of
initiation of trial; patients can have had prior treatment(s) with one or more of the
agents if they are initiating a new treatment with another agent on the list, provided
they have had at least a 2 week "washout" period
- Patients currently taking anti-diarrheal medications or therapy
- Patients undergoing hemodialysis
- Patients with known allergic or hypersensitivity reaction to probiotics, yoghurt, or
similar diet or supplemental products
- Acute or chronic diarrhea, including lactose intolerance, gluten or other dietary
sensitivity resulting in gastrointestinal symptoms
- Pregnant or nursing patients
- Known human immunodeficiency virus (HIV) positive
- Prior abdominal surgery resulting in a stoma, ostomy, fistula, or other anatomic
defect
- Concurrent or near future radiotherapy; prior, completed radiotherapy allowed; any
radiotherapy within the vicinity of the GI tract must have been completed at least 4
weeks prior to start of trial
- Treatment with any investigational drug within 4 weeks prior to enrollment
- Current treatment with antibiotics or other gut motility agents within 2 weeks of
starting study medication
- Abnormal thyroid function that is not controlled with medication
- Patients taking other dietary supplements within 2 weeks of starting study medication
- Any other serious or uncontrolled illness which, in the opinion of the investigator,
makes it undesirable for the patient to enter the trial
Intervention(s):
dietary supplement: Lactobacillus plantarum strain 299v
dietary supplement: Lactobacillus acidophilus probiotic
dietary supplement: placebo
other: laboratory biomarker analysis
other: questionnaire administration
procedure: quality-of-life assessment
dietary supplement: Bifidobacterium lactis probiotic supplement
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
650-736-1252